Watt A H, Hutchings A, Stephens M R, Routledge P A
Br J Clin Pharmacol. 1986 May;21(5):525-8. doi: 10.1111/j.1365-2125.1986.tb02836.x.
Amiodarone is a useful antiarrhythmic agent whose pharmacokinetics are incompletely characterised. In order to optimise efficacy of an antiarrhythmic drug, information regarding plasma concentrations achieved during use of the drug is necessary. We report plasma amiodarone and desethylamiodarone concentrations in eight patients following intravenous infusion at a rate of 175 mg h-1 for the first 2 h, followed by infusion at a rate of 50 mg h-1 for a further 46 h a regimen very similar to that recommended by the manufacturers. In at least three of eight patients plasma concentrations were below the suggested therapeutic range of 1.0-2.5 mg l-1 from 3 to 16 h after the infusion was started. Our data suggests that larger doses of intravenous amiodarone than those previously recommended may be necessary to obtain optimal benefit from the drug.
胺碘酮是一种有用的抗心律失常药物,其药代动力学尚未完全明确。为了优化抗心律失常药物的疗效,了解药物使用期间达到的血浆浓度信息是必要的。我们报告了8例患者静脉输注胺碘酮后的血浆胺碘酮和去乙基胺碘酮浓度,输注方案为:前2小时以175毫克/小时的速率输注,随后46小时以50毫克/小时的速率输注,该方案与制造商推荐的方案非常相似。在8例患者中,至少有3例在输注开始后3至16小时血浆浓度低于建议的治疗范围1.0 - 2.5毫克/升。我们的数据表明,可能需要比先前推荐剂量更大的静脉胺碘酮剂量才能从该药物中获得最佳益处。